When clozapine appears at a dance event…

References

• Giné C, Vilamala M, Espinosa I, et al. Crystals and tablets in the Spanish ecstacy market 2000-2014: are they the same or different in terms of purity and adulteration? Forensic Sci Int. 2016;263:164–168.
   Google Scholar
• Van der Gouwe D, Brunt T, van Laar M, van der Pol P. Purity, adulteration and price of drugs bought on-line versus off-line in the Netherlands. Addiction. 2016;112:640–648.
   Google Scholar
• Brunt T, Nagy C, Bücheli A, et al. Drug testing in Europe: monitoring results of the Trans European Drug Informatio (TEDI) project. Drug Test Anal. 2017;9:188–198.
   Google Scholar
• Solimini R, Rotolo MC, Pellegrini M, et al. Aldulteration practices of psychoactive illicit drugs: an updated review. Curr Pharm Biotechnol. 2017;18:524–530.
   Google Scholar
• Barbera N, Busardo FP, Indorato F, et al. The pathogenetic role of adulterants in 5 cases of drug addicts with a fatal outcome. Forensic Sci Int. 2013;227:74–76.
   Google Scholar
• Blanckaert P, van Amsterdam J, Brunt T, et al. 4-Methyl-amphetamine: a health threat for recreational amphetamine users. J Psychopharmacol. 2013;27:817–822.
   Google Scholar
• Blanckaert P, Vanquekelberghe S, Coopman V, et al. Identification and characterisation of 4-chloromethamphetamine (4-CMA) in seized ecstacy - a risk to public health. Forensic Sci Int. 2018;288:173–180.
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation; [cited 2019 May 11]. Available from: http://www.emcdda.europa.eu/system/files/publications/8870/2018-2489-td0118414enn.pdf.
   Google Scholar
• Subramanian S, Völlm BA, Huband N. Clozapine dose for schizophrenia. Cochrane Database Syst Rev. 2017;6:CD009555.
   Google Scholar
• Wilby KJ, Johnson EG, Johnson HE, et al. Evidence-based review of pharmacotherapy used for Parkinson’s disease psychosis. Ann Pharmacother. 2017;51:682–695.
   Google Scholar
• De Berardis D, Rapini G, Olivieri L, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf. 2018;9:237–256.
   Google Scholar
• Winckel K, Siskind D. Clozapine in primary care. Aust Prescr. 2017;40:231–236.
   Google Scholar
• Kar N, Barreto S, Chandavakar R. Clozapine monitoring in clinical practice: beyond the mandatory requirements. Clin Psychopharmacol Neurosci. 2016;14:323–329.
   Google Scholar
• Stanworth D, Hunt NC, Flanagan RJ. Clozapine - a dangerous drug in a clozapine-naive subject. Forensic Sci Int. 2012;214:e23–5.
   Google Scholar
• Pokorny R, Finkel MJ, Robinson WT. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm Res. 1994;11:1221.
   Google Scholar
• Havnen G, Beck L, Lindqvist R. A dose as low 100 mg of clozapine can lead to severe toxicity in clozapine-naive individuals. Clin Toxicol. 2009;47:509.
   Google Scholar
• Patteet L, Maudens KE, Sabbe B, et al. High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry. Clin Chim Acta. 2014;429:51–58.
   Google Scholar
• Calle P, Sundahl N, Maudens K, et al. Medical emergencies related to alcohol and illicit drugs at an annual nocturnal indoor electronic dance music event. Prehosp Dis Med. 2018;33:71–76.
   Google Scholar
• Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195–235.
   Google Scholar
• Ackenheil M. Clozapine - pharmacokinetic investigations and biochemical effects in man. Psychopharmacology (Berl). 1989;99(supplement 1):S32–S37.
   Google Scholar
• Patteet L, Maudens KE, Vermeulen Z, et al. Retrospective evaluation of therapeutic drug monitoring of clozapine and norclozapine in Belgium using a multidrug UHPLC-MS/MS method. Clin Biochem. 2014;47:336–339.
   Google Scholar
• Couchman L, Morgan PE, Spencer EP, et al. Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex). Ther Drug Monit. 2010;32:624–627.
   Google Scholar
• Helander A, Bäckberg M, Hultén P, et al. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. Forensic Sci Int. 2014;243:23–29.
   Google Scholar
• Walterscheid JP, Phillips GT, Lopez AE, et al. Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. Am J Forensic Med Pathol. 2014;35:20–25.
   Google Scholar
• Graddy R, Buresh M, Rastegar D. New and emerging illicit psychoactive substances. Med Clin N Am. 2018;102:697–714.
   Google Scholar
• Novel Psychoactive Treatment UK Network NEPTUNE. Guidance on the clinical management of acute and chronic harms of club drugs and novel psychoactive substances; 2015 [cited 2019 May 11]. Available from: http://neptune-clinical-guidance.co.uk/
   Google Scholar